Adam Monroe brings more than 30 years of industrial biotechnology experience to the CEO role, with extensive expertise in the agriculture, food, beverage, and nutrition industries. Having joined the Zymtronix board in 2020 and now serving as CEO, Monroe's deep understanding of enzyme innovation, markets, production, sales, and logistics makes him uniquely qualified to lead the company's growth initiatives. Before joining Zymtronix, Monroe served as CEO of Panaceutics Nutrition and as President-Americas for Novozymes, where he led a $900 million enzyme and microbials business across North and South America.